Thrombolytic therapy in older acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding
暂无分享,去创建一个
Eric E. Smith | Deepak L. Bhatt | E. Peterson | L. Schwamm | G. Fonarow | L. Liang | Adrian F. Hernandez | A. Kosinski | Y. Xian | T. Inohara
[1] H. Naess,et al. Intravenous Thrombolysis in Ischemic Stroke Patients With Active Cancer , 2018, Front. Neurol..
[2] K. Furie,et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. , 2018, Stroke.
[3] W. Powers,et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2018, Stroke.
[4] B. Yoon,et al. Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer , 2017, BioMed research international.
[5] Eric E. Smith,et al. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2016, Stroke.
[6] P. Sobolewski,et al. Safety of intravenous thrombolysis for acute ischaemic stroke including concomitant neoplastic disease sufferers – experience from Poland , 2015, International journal of clinical practice.
[7] S. Lageman,et al. National Institute Of Neurological Disorders And Stroke , 2014 .
[8] Mary G. George,et al. Factors influencing the decline in stroke mortality: A statement for healthcare professionals from the American Heart Association/American Stroke Association , 2013 .
[9] J. Suarez,et al. Thrombolysis for Acute Ischemic Stroke in Patients With Cancer: A Population Study , 2013, Stroke.
[10] W. Powers,et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.
[11] G. Moretto,et al. Intravenous Alteplase for acute ischemic stroke in patients with current malignant neoplasm , 2013, Journal of the Neurological Sciences.
[12] L. Deangelis,et al. Use of recombinant tissue plasminogen activator in cancer patients with acute stroke , 2012, Journal of Neuro-Oncology.
[13] Eric E. Smith,et al. Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit. , 2012, American heart journal.
[14] J. Masjuán,et al. Off‐label intravenous thrombolysis in acute stroke , 2012, European journal of neurology.
[15] Eric E. Smith,et al. Representativeness of the Get With The Guidelines–Stroke Registry: Comparison of Patient and Hospital Characteristics Among Medicare Beneficiaries Hospitalized With Ischemic Stroke , 2012, Stroke.
[16] Eric E. Smith,et al. Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy. , 2011, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[17] Deepak L. Bhatt,et al. Clopidogrel with or without omeprazole in coronary artery disease. , 2010, The New England journal of medicine.
[18] I. Casado-Naranjo,et al. Intravenous thrombolysis for acute stroke in patients with cancer , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[19] M. Kaste,et al. Off-Label Thrombolysis Is Not Associated With Poor Outcome in Patients With Stroke , 2010, Stroke.
[20] Eric E. Smith,et al. Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The Guidelines-Stroke , 2010, Circulation. Cardiovascular quality and outcomes.
[21] Adrian F Hernandez,et al. Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. , 2009, American heart journal.
[22] Deepak L. Bhatt,et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. , 2008, Circulation.
[23] M. Kaste,et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.
[24] Koroshetz Wj,et al. Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.
[25] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[26] E. Weeda,et al. Association between comorbid cancer and outcomes among admissions for acute ischemic stroke receiving systemic thrombolysis , 2019, International journal of stroke : official journal of the International Stroke Society.
[27] P Trouillas,et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. , 1998, Lancet.